FWIW, I was sketching out the situation in the US healthcare market generally, and not specifically referring to the insulin situation. To expand slightly (all

FWIW, I was sketching out the situation in the US healthcare market generally, and not specifically referring to the insulin situation. To expand slightly (all IM opinion/observation): a) Often, there isn't a 'market', as there might not be multiple competitive options for each disease. b) Even in situations where there are (say) two roughy similar treatments for a disease, market forces don't always apply - manufacturers differentiate via other routes and try to avoid price erosion. c) It's uncertain how often price directly influences prescribing decisions (in the US, or indeed in many countries).